TORONTO, October 12, 2021– (COMMERCIAL THREAD) –Cybin Inc. (NEO: CYBN) (AMERICAN NYSE: CYBN) (“Cybine“or the”Society“), a biotechnology company focused on advancing psychedelic therapies, today announced that it has filed an international patent application for methods of delivering psychedelic drugs by inhalation and devices for performing these methods.
The application, governed by the Patent Cooperation Treaty (“PCT”), offers the possibility of obtaining patent coverage in 153 countries.
The Company believes that the administration of psychedelic drugs by inhalation can overcome the main obstacles encountered by traditional oral administration of drugs. Specifically, the company expects inhalation administration to facilitate optimized timing of psychedelic sessions versus oral administration of the same compounds, lower doses of psychedelic therapies while maintaining efficacy and providing patients with benefits. More control health care providers during psychedelic sessions.
Filed in support of the Company CYB004 A preclinical development program, the PCT repository serves to augment the company’s library of drug delivery modalities aimed at optimal delivery of psychedelics and further strengthens Cybin’s growing intellectual property portfolio.
The PCT dossier also includes support for future research programs regarding various systems that seek to minimize negative side effects in psychedelic psychotherapy patients, methods that allow lower and sub-psychedelic doses without affecting the effectiveness of treatment and increasing long-term effectiveness of psychedelic sessions.
âThe continued progress of our research programs guides our discovery of new molecules and differentiating therapeutic approaches. Continuous innovation, as evidenced by our expanding intellectual property portfolio, positions Cybin as a leading innovator in the development of putative psychedelic treatments for a variety of mental health issues. “said Doug Drysdale, CEO of the company.
Cybin is a leading biotechnology company focused on progress psychedelic therapy using proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.
Cautions and forward-looking statements
Certain statements contained in this press release constitute forward-looking information. All statements other than statements of historical fact contained in this press release, including, without limitation, statements regarding the future, strategy, plans, objectives, goals and targets of Cybin, and all statements preceded, followed or which include the words “believe”, “expect”, “aim”, “intend”, “plan”, “continue”, “will”, “could”, “could “,” Anticipate “,” estimate “,” anticipate “,” predict “,” project “,” seek “,” should “or similar or negative expressions thereof, are forward-looking statements. Forward-looking statements contained in this press release include statements regarding the Company’s development of innovative drug delivery systems, novel formulation approaches and potential treatment regimens for psychiatric disorders, and a proprietary development strategy and development. medicinal psychedelics with improved dosage efficiency and therapeutic indices to address unmet medical needs.
These forward-looking statements are based on reasonable assumptions and estimates of the management of the Company at the time these statements were made. Actual future results may differ materially, as forward-looking statements involve risks, uncertainties and other known and unknown factors that may cause the actual results, performance or achievements of the Company to differ materially from the results, performance or achievements. futures expressed or implied by these forward-looking statements. These factors include, among others: the implications of the COVID-19 pandemic on the Company’s operations; fluctuations in general macroeconomic conditions; fluctuations in the securities markets; expectations regarding the size of the psychedelics market; the Company’s ability to successfully achieve its business objectives; growth plans; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions on the markets in which the Company operates; and the risk factors set out in the Company’s management report for the quarter ended June 30, 2021 and the Company’s listing statement dated November 9, 2020, which are available under the Company’s profile on www.sedar.com and with the United States Securities and Exchange Commission on EDGAR at www.sec.gov. Although the forward-looking statements contained in this press release are based on what the management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with these. forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or expected. Readers should not place undue reliance on the forward-looking statements and information contained in this press release. The Company assumes no obligation to update forward-looking statements of beliefs, opinions, projections or other factors, if they change, except as required by law.
Cybin makes no medical, therapeutic or health claims regarding the products offered by Cybin. The United States Food and Drug Administration, Health Canada, or other similar regulatory authorities have not evaluated claims regarding psilocybin, psychedelic tryptamine, tryptamine derivatives, or other psychedelic compounds or nutraceuticals. The effectiveness of these products has not been confirmed by approved research. There can be no assurance that the use of psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic or nutraceutical compounds will diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. Cybin has not conducted clinical trials for the use of its offered products. Any reference to the quality, consistency, efficacy and safety of potential products does not imply that Cybin has verified them in clinical trials or that Cybin will complete such trials. If Cybin cannot obtain the approvals or research necessary to market its business, it could have a material adverse effect on Cybin’s performance and operations.
The Neo Bourse Inc. has neither approved nor disapproved the contents of this press release and is not responsible for the relevance and accuracy of its contents.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20211012005066/en/
Tim Regan / Scott Eckstein
KCSA strategic communication
Lisa M. Wilson
Site Communications, Inc.